INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT

Pomerantz LLP is investigating securities fraud claims against EyePoint, Inc. following the company's announcement that its Phase 3 clinical trial for DURAVYU failed to meet its primary endpoint against Regeneron's Eylea. The stock plummeted 66.98% to $4.87 per share on August 17, 2026.